ENZY Enzymatica AB (publ)
Enzymatica AB (publ), a life science company, develops and sells medical devices for infectious diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care under Penzyme technology. The company was incorporated in 2007 and is headquartered in Lund, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Enzymatica (STO: ENZY)
›
Enzymatica (STO: ENZY) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 17 employees.
The shares were at 2.270 SEK on 19 November 2026, up 18.2% over 52 weeks. Its 52-week range is 1.550 SEK to 3.400 SEK: the price is 33.2% below the high and 46.5% above the low.
Its market capitalisation is 551.01M SEK.
Enzymatica reports return on equity of -41.8%, an operating margin of -78.3% and revenue down 2.9% year over year.
Its debt exceeds its cash by 7.11M SEK, a debt-to-equity ratio of 0.01. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.